HomeCompareTSCAP vs ABBV

TSCAP vs ABBV: Dividend Comparison 2026

TSCAP yields 25.17% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $4.9K in total portfolio value· pulled ahead in Year 10
10 years
TSCAP
TSCAP
● Live price
25.17%
Share price
$25.35
Annual div
$6.38
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$99.8K
Annual income
$11,317.81
Full TSCAP calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TSCAP vs ABBV

📍 ABBV pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSCAPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSCAP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSCAP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSCAP
Annual income on $10K today (after 15% tax)
$2,139.52/yr
After 10yr DRIP, annual income (after tax)
$9,620.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $12,246.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSCAP + ABBV for your $10,000?

TSCAP: 50%ABBV: 50%
100% ABBV50/50100% TSCAP
Portfolio after 10yr
$102.2K
Annual income
$18,521.77/yr
Blended yield
18.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TSCAP
Analyst Ratings
5
Buy
6
Hold
Consensus: Hold
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSCAP buys
0
ABBV buys
0
No recent congressional trades found for TSCAP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSCAPABBV
Forward yield25.17%3.12%
Annual dividend / share$6.38$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$99.8K$104.7K
Annual income after 10y$11,317.81$25,725.73
Total dividends collected$63.3K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TSCAP vs ABBV ($10,000, DRIP)

YearTSCAP PortfolioTSCAP Income/yrABBV PortfolioABBV Income/yrGap
1$13,217$2,517.08$11,559$438.51+$1.7KTSCAP
2$17,251$3,109.20$13,494$640.86+$3.8KTSCAP
3$22,252$3,792.77$15,951$945.97+$6.3KTSCAP
4$28,382$4,572.06$19,152$1,413.89+$9.2KTSCAP
5$35,818$5,450.02$23,443$2,146.38+$12.4KTSCAP
6$44,754$6,428.10$29,391$3,321.96+$15.4KTSCAP
7$55,393$7,506.25$37,948$5,265.87+$17.4KTSCAP
8$67,953$8,682.86$50,795$8,596.74+$17.2KTSCAP
9$82,665$9,954.87$71,034$14,549.41+$11.6KTSCAP
10← crossover$99,769$11,317.81$104,715$25,725.73$4.9KABBV

TSCAP vs ABBV: Complete Analysis 2026

TSCAPStock

TriState Capital Holdings, Inc. operates as the bank holding company for TriState Capital Bank that provides various commercial and private banking services to middle-market businesses and high-net-worth individuals in the United States. The company operates in two segments, Bank and Investment Management. Its deposit products include checking accounts, money market deposit accounts, and certificates of deposit, as well as promontory's certificate of deposit account registry services and insured cash sweep services. The company also provides loans that are secured by cash, marketable securities, cash value life insurance, residential property, or other financial assets, as well as commercial and industrial loans, commercial real estate loans, personal loans, asset-based loans, acquisition financing, and letters of credit. In addition, it offers liquidity and treasury management services, such as online balance reporting, online bill payment, remote deposit, liquidity, wire and automated clearing house, foreign exchange, and controlled disbursement services; and equity and fixed income advisory and sub-advisory services to third party mutual funds and series trust mutual funds, as well as separately managed accounts primarily comprising ultra-high-net-worth and institutional clients that include corporations, ERISA plans, Taft-Hartley funds, municipalities, endowments, and foundations. Further, the company provides cash management services; and capital market services, such as interest rate swaps and investment management products, as well as engages in wholesaling and marketing the investment products and services. It offers its products and services through its main office located in Pittsburgh, Pennsylvania, as well as through its four additional representative offices in Cleveland, Ohio; Philadelphia, Pennsylvania; Edison, New Jersey; and New York, New York. The company was incorporated in 2006 and is headquartered in Pittsburgh, Pennsylvania.

Full TSCAP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TSCAP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSCAP vs SCHDTSCAP vs JEPITSCAP vs OTSCAP vs KOTSCAP vs MAINTSCAP vs JNJTSCAP vs MRKTSCAP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.